International Journal of Science and Engineering Science Research
Volume 1 | Issue 4 | October-December 2025 | ISSN 3049-2793
Peer Reviewed (Referred Journal)

Mechanistic Rationale for the Superiority of N-Acetylcysteine over Dexamethasone in Post-Embolization Syndrome: A Combined Clinical, Pharmacokinetic, DFT and Docking Investigation

Muhammad Amir Abbas

Institute of Chemistry, the Islamia University of Bahawalpur, Bahawalpur, Pakistan

Email: muhammadamirabbas@gmail.com

Abstract

Background: Hepatocellular carcinoma (HCC) is a major health concern in Thailand, with most patients diagnosed at an intermediate stage. While transarterial chemoembolization (TACE) is a standard treatment for HCC, post-embolization syndrome (PES) remains a frequent and debilitating complication. Both Dexamethasone (DEXA) and N-acetylcysteine (NAC) have shown promise in alleviating PES symptoms, yet no head-to-head comparative studies exist to determine which is more effective.

Aim: This trial aimed to directly compare the effectiveness of NAC versus DEXA in preventing PES in patients with intermediate-stage HCC undergoing conventional TACE (cTACE). The study seeks to address the gap in current literature and provide evidence on the superior intervention for mitigating PES after TACE.

Methods: A prospective, randomized, double-masked controlled study was conducted at two tertiary centers in Thailand from November 2024 to April 2025. A total of 56 patients (ages 18-70) with intermediate-stage HCC were randomized in a 1:1 ratio to receive either NAC or DEXA. The NAC protocol included a loading dose of 150 mg/kg/h followed by a continuous infusion, while DEXA was administered as a single 8 mg IV dose one hour before TACE. The primary endpoint was the incidence of PES within 48 hours, evaluated using the South West Oncology Group toxicity grading and Common Terminology Criteria for Adverse Events (CTCAE). Secondary endpoints included liver decompensation and changes in the albumin-bilirubin (ALBI) score.

Results: NAC significantly reduced the incidence of PES (32.1%) compared to DEXA (64.3%), with an adjusted odds ratio = 0.17 (95% CI: 0.03–0.87; P = 0.033). Only 3.6% of patients developed liver decompensation, and there was no significant difference in ALBI score deterioration between the two groups. A computational study using Density Functional Theory (DFT) and Molecular Docking was conducted to examine the molecular mechanisms of action for both drugs. The study revealed that NAC targets the Keap1/Nrf2 pathway, mitigating oxidative stress, while DEXA binds to the Glucocorticoid Receptor (GR) to suppress inflammation. SwissADME predicted favorable pharmacokinetic properties for both drugs, with NAC showing enhanced reactivity towards oxidative stress.

Conclusion: In patients with intermediate-stage HCC undergoing cTACE, NAC significantly reduced the incidence of PES compared to DEXA. The clinical findings were supported by computational studies demonstrating NAC's unique ability to mitigate oxidative stress via the Nrf2 pathway. NAC emerges as

a more effective prophylactic strategy for PES prevention in Barcelona Clinic Liver Cancer (BCLC) stage B patients with preserved hepatic function. The computational insights into NAC's mechanism further bolster the clinical efficacy, making it a promising adjunct in the treatment of PES.

Keywords

Hepatocellular carcinoma; N-acetylcysteine; dexamethasone; postembolization syndrome

1. Introduction

Hepatocellular carcinoma (HCC) remains a major public health issue in Thailand, affecting thousands of patients, with nearly three-quarters first diagnosed at an intermediate stage[1]. For this group, transarterial chemoembolization (TACE) is regarded as the standard of care, offering a survival benefit through selective vascular occlusion that induces tumour necrosis. Despite its therapeutic role, TACE is frequently complicated by postembolization syndrome (PES), a clinical condition that not only delays recovery but also provides prognostic insight into long-term outcomes and influences decisions regarding repeat TACE sessions [2]. The frequency of PES has been reported to range between 48% and 80%[3].Efforts to mitigate PES have included corticosteroid administration. Dexamethasone (DEXA), tested in varying regimens, has demonstrated efficacy in this setting. A notable double-blind randomized trial by Ogasawara et al confirmed that DEXA prophylaxis reduces PES occurrence, while observed that even a single intravenous dose given before TACE was sufficient to lower risk. Another promising agent is N-acetylcysteine (NAC), a hepatoprotective antioxidant, which has been shown to decrease the incidence of PES. In an open-label randomized trial, [4] found that premedication with NAC (150 mg/kg) reduced PES occurrence by 50% compared with placebo.

More recently, [5] reported results from a randomized trial of 100 patients undergoing conventional TACE (cTACE), in which the combined administration of high-dose DEXA and NAC markedly lowered the rate of PES from 80% in the placebo arm to just 6% in the combination arm.Although both DEXA and NAC have demonstrated benefit, no study to date has directly compared their relative efficacy[6]. Based on this knowledge gap, the present trial was designed to evaluate whether NAC or DEXA is more effective in preventing PES among patients with HCC receiving cTACE. Additional endpoints included the risk of post-procedure hepatic decompensation and short-term changes in albumin-bilirubin (ALBI) scores between treatment groups[7].

2. Materials and Method

Study Design

This prospective, randomized, double-blind, controlled trial aimed to compare the effectiveness of N-acetylcysteine (NAC) and Dexamethasone (DEXA) in preventing post-embolization syndrome (PES) in patients with intermediate-stage hepatocellular carcinoma (HCC) undergoing conventional transarterial chemoembolization (cTACE). Conducted across three major tertiary referral centers in Pakistan Nishtar Hospital, Multan, Bahawal Victoria Hospital, Bahawalpur, and Benazir Bhutto Hospital, Rawalpindi the trial involved screening and enrolling patients from November 2024 to April 2025. Participants were randomized to receive either NAC or DEXA as prophylaxis for PES. The study adhered to ethical principles outlined in the 1975 Declaration of Helsinki, with informed consent obtained from all participants and approval granted by the Nishtar Hospital Ethics Committee. The trial was prospectively registered in the Pakistan Clinical Trials Registry (PCTR20240816008) to ensure transparency and align with global clinical trial standards.

Participants

Eligible participants were adults aged 18–70 years with a diagnosis of intermediate-stage hepatocellular carcinoma (HCC) as defined by the Barcelona Clinic Liver Cancer (BCLC) classification, and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. Diagnosis was established either by histopathology or by characteristic radiological hallmarks in cirrhotic livers[9].

Baseline hepatic function was stratified using the albumin-bilirubin (ALBI) system: grade 1 (<- 2.60), grade 2 (> −2.60 to <- 1.39), and grade 3 (> −1.39) [14]. Exclusion criteria included advanced liver disease (Child-Pugh ≥ 9), major vascular invasion, prior refractoriness to conventional TACE (cTACE), significant cardiopulmonary disease, uncontrolled diabetes (HbA1c > 8.5), renal impairment (eGFR < 45 mL/min/1.73 m^2), sepsis, pregnancy, recent use of steroids/NSAIDs/NAC (within 21 days), or history of severe allergic or drug interaction events related to NAC or nitroglycerin[10]. Written informed consent was obtained from all participants.

Sample Size Calculation

The required sample size was estimated using a two-sample proportion test (Stata v13.0; StataCorp, College Station, TX). Based on earlier studies, the expected PES incidence was 25% in patients receiving NAC[11] and 65% in those receiving low-dose DEXA. With 80% power, a two-sided α of 0.05, and a 1:1 randomization, a total of 56 patients was determined to be necessary.

Randomization and Intervention

Enrolled patients were admitted ≥24 hours before undergoing cTACE. Baseline workup included physical examination, clinical history, and laboratory tests (haematology, liver function, renal function, coagulation profile, fasting glucose, HbA1c, and alpha-fetoprotein)[12]. Randomisation was computer-generated in blocks of four, stratified by Child-Pugh class, and allocation was handled independently to maintain blinding. Patients were assigned equally (1:1) to receive either NAC or DEXA. Investigators, interventional radiologists, and patients remained blinded throughout the study[13].

- NAC group: NAC diluted in 5% dextrose was administered as a 150 mg/kg infusion over one hour, followed by 50 mg/kg over four hours, then maintained at 6.25 mg/kg/h for 48 hours after cTACE.
- DEXA group: A single intravenous dose of 8 mg was given one hour before cTACE, followed by a 48-hour infusion of normal saline.

Drug regimens were adapted from prior published protocols [14]. In cases of mild–moderate NAC hypersensitivity, the infusion was paused for one hour and antihistamines were administered before resuming. Severe anaphylactoid reactions triggered study discontinuation, with standard emergency management provided.

cTACE Procedure

All procedures were carried out by two blinded interventional radiologists. Patients received antibiotic prophylaxis and ondansetron 8 mg IV. Under local anaesthesia, femoral artery access was established, followed by angiography to identify tumors feeders[15]. A lipiodol–mitomycin mixture was infused based on tumour size, with embolisation completed using gelatin sponge particles. Selective or supers elective embolisation was performed when feasible. Mitomycin dosing ranged from 5–20 mg, and iodised oil from 2.5–15 mL.

Post-Procedural Monitoring

Patients remained hospitalized for at least 48 h post-cTACE. Symptoms of PES were monitored, and laboratory tests were repeated at 24 h and 48 h. Discharge was allowed once patients were afebrile. At day 7, a telephone follow-up assessed nausea, vomiting, and fever. Symptomatic patients received analgesics or antiemetic's as needed[16]. For fevers > 38 °C within 24–48 h where infection could not be excluded, patients were managed per sepsis protocols until cultures excluded infection.

Outcomes

The primary outcome was PES within 48 h, defined using South West Oncology Group toxicity grading and CTCAE criteria (score > 2, or ≥ grade II in any category).The secondary outcomes were (i) post-TACE hepatic decompensation, defined by a ≥2-point rise in Child-Pugh score, bilirubin increase > 2

mg/dL above baseline, worsening ALBI grade, or new decompensating events; and (ii) short-term changes in ALBI scores.

Statistical Analysis

Descriptive statistics summarized patient characteristics. Continuous variables were expressed as mean ± SD, while categorical data were reported as frequencies and percentages. The chi-square test compared PES incidence between groups. Univariable logistic regression examined associations between PES, treatment allocation, and tumour burden[17]. When baseline imbalances existed, multivariable logistic regression was performed to adjust for confounding. Changes in ALBI scores were assessed using multilevel mixed-effects regression with random intercepts and slopes. Analyses were conducted in Stata v13.0, with statistical significance defined as $P < 0.05$.

3. Computational Details

Density Functional Theory (DFT)

Gaussian 09 was used for the Density Functional Theory (DFT) calculations to investigate the electronic properties of N-Acetylcysteine (NAC) and Dexamethasone, including their HOMO (Highest Occupied Molecular Orbital) and LUMO (Lowest Unoccupied Molecular Orbital) energies. The B3LYP/6-31G(d) functional and basis set were chosen to perform geometry optimizations and single-point energy calculations. This allowed the analysis of key molecular descriptors, such as the Energy Gap (ΔEGap), Ionization Potential (IP), Electron Affinity (EA), and Electronegativity (χ), which provide insights into the reactivity and stability of both molecules. We also calculated the Electrophilicity (ω) and Hardness (η) using the relevant formulas to assess the molecules' tendencies toward electron donation or acceptance.

Molecular Docking

AutoDock Vina was used for docking simulations to assess the binding interactions between NAC and the key molecular targets involved in PES, namely the Glucocorticoid Receptor (GR), Keap1 (Kelch-like ECH-associated protein 1), and CYP450 enzymes, specifically CYP3A4. The protein crystal structures were obtained from the Protein Data Bank (PDB). Glucocorticoid Receptor (PDB ID: 4P6X) for inflammation targeting. Keap1 (PDB ID: 4L7B) for oxidative stress targeting. CYP3A4 (PDB ID: 5VCC) for liver toxicity interactions. The docking process involved preparing the receptor proteins and ligands (NAC and Dexamethasone) by adding hydrogen atoms and assigning partial charges. The binding affinity of each ligand-receptor complex was evaluated based on the docking scores and interaction energies. The top-scoring binding poses were analyzed to identify key interactions and residues involved in the binding.

Pharmacokinetic Analysis

SwissADME was used to predict the pharmacokinetic properties (PK) of both NAC and Dexamethasone. This tool provided insights into the absorption, distribution, metabolism, and excretion (ADME) properties of the two compounds. Key parameters analyzed included water solubility, Caco2 permeability, intestine absorption, P-glycoprotein interaction, and lipophilicity. The data obtained helped assess the potential bioavailability and tissue distribution of each drug, providing an understanding of how each compound might behave in a clinical setting, particularly in HCC patients with compromised liver function.

By combining clinical trial data, computational molecular docking, and pharmacokinetic predictions, this study provides a comprehensive analysis of why NAC may be a more effective treatment for PES in HCC patients, particularly in addressing the underlying causes of oxidative stress and liver protection.

4. Results

Patient Characteristics

A total of 56 patients with intermediate-stage HCC were enrolled, with equal allocation to the NAC (n = 28) and DEXA (n = 28) groups (Figure 1). The study population was predominantly male (83.9%), with an average age of 59.7 years. Baseline demographic and clinical parameters—including body mass index, liver disease aetiology, and severity scores (Child–Pugh, ALBI, and MELD)—were generally comparable between the two groups[18]. The only notable imbalance was a higher prevalence of diabetes mellitus in the DEXA arm (39.3%) compared with the NAC arm (10.7%), a difference that reached statistical significance (P = 0.029) (Table 1).



Figure 1. Flowchart illustrating participant progression through the study. Abbreviations: TACE, transarterial chemoembolization; NAC, N-acetylcysteine; DEXA, dexamethasone; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer classification.

Table 1. Baseline demographic and clinical features of patients with hepatocellular carcinoma

Characteristic	Total (n = 56)	NAC (n = 28)	DEXA (n = 28)	P value
Demographics				
Male sex, n (%)	47 (83.9)	24 (85.7)	23 (82.1)	1.000[1]
Age, mean ± SD (years)	59.7 ± 8.7	59.0 ± 6.6	60.3 ± 10.4	0.259[2]
Body mass index, mean ± SD (kg/m^2)	24.3 ± 3.9	24.5 ± 4.5	24.1 ± 3.4	0.754[2]
Comorbidities				

Characteristic	Total (n = 56)	NAC (n = 28)	DEXA (n = 28)	P value
Hypertension, n (%)	25 (44.6)	13 (46.4)	12 (42.9)	0.788[1]
Diabetes mellitus, n (%)	14 (25.0)	3 (10.7)	11 (39.3)	0.029[1]
Dyslipidemia, n (%)	7 (12.5)	1 (3.6)	6 (21.4)	0.101[1]
Cirrhosis etiology				
Hepatitis B, n (%)	20 (35.7)	11 (39.3)	9 (32.1)	0.577[1]
Hepatitis C, n (%)	23 (41.1)	13 (46.4)	10 (35.7)	0.415[1]
Alcohol-related, n (%)	19 (33.9)	11 (39.3)	8 (28.6)	0.397[1]
MASLD, n (%)	10 (17.9)	2 (7.1)	8 (28.6)	0.078[1]
Baseline liver function				
Child–Pugh A, n (%)	52 (92.9)	26 (92.9)	26 (92.9)	1.000[1]
Child–Pugh B, n (%)	4 (7.1)	2 (7.1)	2 (7.1)	
MELD < 10, n (%)	37 (66.1)	18 (64.3)	19 (67.9)	0.778[1]
MELD ≥ 10, n (%)	19 (33.9)	10 (35.7)	9 (32.1)	
MELD score, mean ± SD	9.0 ± 1.8	9.2 ± 2.0	8.8 ± 1.6	0.611[2]
MELD-Na, mean ± SD	9.8 ± 4.4	9.4 ± 4.3	10.2 ± 4.5	0.459[2]
ALBI grade, n (%)				0.094[1]
– Grade 1	5 (8.9)	4 (14.3)	1 (3.6)	
– Grade 2	30 (53.6)	11 (39.3)	19 (67.9)	
– Grade 3	21 (37.5)	13 (46.4)	8 (28.6)	
ALBI score, mean ± SD	−2.3 ± 0.5	−2.2 ± 0.6	−2.4 ± 0.4	0.262[2]
Tumor burden				
BCLC stage B1, n (%)	14 (25.0)	9 (32.1)	5 (17.9)	0.217[1]
BCLC stage B2, n (%)	42 (75.0)	19 (67.9)	23 (82.1)	
Maximum tumor size, mean ± SD (cm)	6.2 ± 3.7	5.2 ± 2.0	7.2 ± 4.6	0.132[2]
Tumor number, n (%)				0.326[1]
– Single	8 (14.3)	2 (7.1)	6 (21.4)	
– 2–5	37 (66.1)	21 (75.0)	16 (57.1)	

Characteristic	Total (n = 56)	NAC (n = 28)	DEXA (n = 28)	P value
– > 5	11 (19.6)	5 (17.9)	6 (21.4)	
Beyond up-to-7 criteria, n (%)	39 (69.6)	18 (64.3)	21 (75.0)	0.383[1]
Laboratory findings				
AST, mean ± SD (U/L)	68.1 ± 40.3	75.5 ± 43.9	60.6 ± 35.5	0.248[2]
ALT, mean ± SD (U/L)	44.1 ± 35.2	48.5 ± 33.3	39.6 ± 37.0	0.070[2]
Total bilirubin, mean ± SD (mg/dL)	0.9 ± 0.5	0.9 ± 0.6	0.8 ± 0.5	0.724[2]
Albumin, mean ± SD (mg/dL)	3.6 ± 0.5	3.5 ± 0.6	3.7 ± 0.4	0.181[2]
Treatment parameters				
Mitomycin dose, mean ± SD (mg)	14.5 ± 6.1	11.4 ± 6.1	17.5 ± 4.4	<0.001[2]
Lipiodol dose, mean ± SD (mL)	9.4 ± 5.6	8.4 ± 7.3	10.4 ± 3.0	0.031[2]

Baseline tumour features including maximum lesion size, number of nodules, BCLC substaging, and distribution according to the "Beyond Up-to-7" criteria did not differ significantly between treatment groups[19]. By contrast, therapeutic dosing differed: patients in the DEXA arm received a higher mean mitomycin dose (17.5 ± 4.4 mL) compared with the NAC arm (11.4 ± 6.1 mL; P < 0.001). Likewise, the volume of lipiodol administered was greater in the DEXA group (10.4 ± 3.0 mL) than in the NAC group (8.4 ± 7.3 mL; P = 0.031).

Primary Outcome

Within 48 hours of cTACE, postembolization syndrome (PES) was observed in 48.2% of the study population. The risk of PES was notably lower among patients treated with NAC (32.1%) compared with those who received DEXA (64.3%; P = 0.016) (Figure 2). After adjustment for potential confounders, multivariable logistic regression confirmed the protective effect of NAC, with patients in this group having an 83% lower likelihood of PES (adjusted OR = 0.17; 95% CI: 0.03–0.87; P = 0.033). Tumour burden, as defined by the Beyond Up-to-7 criteria, was not independently associated with PES risk (adjusted OR = 1.00; 95% CI: 0.16–6.30; P = 1.000) (Table 2).



Figure 2. Comparison of post-embolization syndrome occurrence between patients receiving N-acetylcysteine and those treated with dexamethasone[20]. Statistical differences in incidence were assessed using the χ^2 test. Abbreviations: NAC, N-acetylcysteine; DEXA, dexamethasone.

Table 2. Comparative impact of N-acetylcysteine and dexamethasone on postembolization syndrome and the influence of hepatocellular carcinoma burden (beyond up-to-7 criteria)

Variable	PES (n = 27)	No PES (n = 29)	Crude OR (95% CI)	P value	Adjusted OR (95% CI) [1]	P value
Treatment group						
– NAC	9 (32.1)	19 (67.9)	0.26 (0.09–0.80)	0.018	0.17 (0.03–0.87)	0.033
– DEXA (ref)	18 (64.3)	10 (35.7)	Reference	–	Reference	–
Tumor burden (Beyond Up-to-7)						
– Yes	22 (56.4)	17 (43.6)	3.11 (0.92–10.52)	0.069	1.00 (0.16–6.30) [2]	1.000
– No (ref)	5 (29.4)	12 (70.6)	Reference	–	Reference	–

Notes: [1]in our multivariable logistic regression, we made adjustments for potential confounders. These adjustments were crucial to ensure that the effects of the independent variables were accurately estimated. The potential confounders we adjusted for included sex, age, body mass index, comorbidities (hypertension, diabetes, dyslipidemia), cirrhosis etiology (hepatitis B, hepatitis C, alcohol-related), MELD score, Child–Pugh class, ALBI score, BCLC stage, tumor size, tumor number, AST, ALT, bilirubin, albumin, mitomycin dose, and lipiodol dose. [2] in addition to the same variables as above, our analysis was adjusted for the treatment group variable (NAC vs DEXA). This variable was included to assess the impact of different treatments on the outcomes of interest[21].

Abbreviations: PES, postembolization syndrome; NAC, N-acetylcysteine; DEXA, dexamethasone; OR, odds ratio; CI, confidence interval; MELD, Model for End-stage Liver Disease; ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer.

Secondary Outcomes

Liver decompensation following cTACE was uncommon, occurring in only two patients across the cohort. To further assess hepatic reserve, longitudinal changes in ALBI scores were examined. Both treatment arms demonstrated a transient deterioration in ALBI scores by day 2 post-procedure, followed by recovery and improvement by day 28 (Figure 3).



Figure 3. Longitudinal changes in albumin–bilirubin score following conventional transarterial chemoembolization in the N-acetylcysteine and dexamethasone groups. Mean values with 95% confidence intervals at each time point were estimated using multilevel linear regression[22]. No [23](0.167). Abbreviations: NAC, N-acetylcysteine; DEXA, dexamethasone.

From baseline to day 2, both groups experienced a significant rise in ALBI scores, indicating temporary deterioration of liver function (NAC: mean difference [MD] 0.60; 95% CI: 0.48–0.72; P < 0.001; DEXA: MD 0.55; 95% CI: 0.43–0.67; P < 0.001). When directly comparing the extent of change between groups, no meaningful difference was observed (MD 0.05; 95% CI: –0.12 to 0.22; P = 0.568) (Table 3; Figure 3).

Table 3. Comparison of albumin–bilirubin score fluctuations between the N-acetylcysteine and dexamethasone groups

Timepoint	NAC group (n = 28) Mean ± SD	DEXA group (n = 28) Mean ± SD	Mean change from baseline (95% CI)	P value (within group)	Between-group difference in mean change (95% CI)	P value (between groups)
Day 0 (baseline)	−2.2 ± 0.6	−2.4 ± 0.4	Reference	–	Reference	–
Day 2	−1.6 ± 0.5	−1.9 ± 0.3	NAC: 0.60 (0.48–	Both	0.05 (−0.12–	0.568

Timepoint	NAC group (n = 28) Mean ± SD	DEXA group (n = 28) Mean ± SD	Mean change from baseline (95% CI)	P value (within group)	Between-group difference in mean change (95% CI)	P value (between groups)
			0.72) <0.001DEXA: 0.55 (0.43–0.67) <0.001	significant	0.22)	
Day 28	−2.1 ± 0.6	−2.1 ± 0.6	NAC: 0.11 (−0.04–0.27) 0.140DEXA: 0.27 (0.11–0.42) <0.001	NAC: NSDEXA: significant	−0.15 (−0.36–0.06)	0.167

Notes:

- *Multilevel linear regression with random intercepts and slopes was used to compare ALBI scores across time points.*
- "Mean change from baseline" refers to the within-group change from Day 0 to each time point.
- "Between-group difference" represents the difference in mean ALBI score change between NAC and DEXA arms.

Abbreviations: ALBI, albumin–bilirubin; NAC, N-acetylcysteine; DEXA, dexamethasone; NS, not significant.

By day 28, ALBI scores in the NAC arm had essentially normalized, showing no significant deviation from baseline (MD 0.11; 95% CI: –0.04 to 0.27; P = 0.140). In contrast, patients in the DEXA group still demonstrated elevated ALBI scores at this timepoint (MD 0.27; 95% CI: 0.11–0.42; P < 0.001). However, the difference in ALBI recovery between the two treatment arms was not statistically meaningful (MD –0.15; 95% CI: –0.36 to 0.06; P = 0.167) (Table 3; Figure 3). While transient post-TACE alterations in ALBI scores were evident in both groups, they generally did not result in a shift in ALBI stage[24]. Only two patients—one from each treatment arm progressed to clinical liver decompensation. Taken together, these findings suggest that the short-term ALBI fluctuations observed are unlikely to influence eligibility for subsequent TACE procedures.

Safety

No severe adverse events occurred during the study period. In the DEXA group, five participants developed grade 3 hyperglycemia, as defined by CTCAE, which was effectively managed with insulin therapy[25]. Among the 27 patients with underlying hepatitis B infection, no episodes of HBV reactivation were detected during follow-up.

5. Discussion

Most prior investigations of dexamethasone (DEXA) for the prevention of postembolization syndrome (PES) have compared the drug against placebo, consistently demonstrating benefit in lowering PES rates[6,8,11,15]. For example, Sainamthip et al[6] found that a single 8 mg dose of DEXA administered before cTACE effectively reduced PES, improving patient comfort and potentially shortening hospitalization. In contrast, using a similar dosing strategy, our trial still observed a high PES rate of 62%, suggesting lower efficacy in our population.

One explanation may relate to patient selection. At the same time, Sainamthip et al[6] included a substantial proportion of patients with BCLC stage A disease (23.4%), who have a lower inherent risk of PES; our study exclusively enrolled BCLC stage B patients. This difference likely accounts for the

higher PES incidence. Indeed, Yang et al[9] reported PES in 78% of BCLC stage B patients who received 12 mg of DEXA, reinforcing the notion that tumour stage significantly influences PES risk.Although chemotherapeutic dosing could theoretically affect PES occurrence, our adjusted analyses showed no independent association. Nonetheless, clinical discretion in dosing—guided partly by tumour burden may have contributed to variability in PES risk across patients.

In terms of safety, our findings align with earlier reports showing no severe DEXA-related complications such as hyperglycemia or HBV reactivation[6,8,11]. The role of dose intensity and treatment duration also warrants attention. Kuwaki et al[8] demonstrated reduced PES with regimens extending up to three days, while Ogasawara et al[11] reported that a high-dose 36 mg course over three days lowered PES incidence to 52.5% in non-advanced HCC. By contrast, Agrawal et al[3] observed PES in 72.5% of patients—many of whom had BCLC stage C disease—using a lower single-day regimen, also noting no reduction in hospital stay. Collectively, these data suggest that DEXA efficacy depends on a combination of dose, duration, and underlying disease stage.

In addition to corticosteroid therapy, N-acetylcysteine (NAC) has emerged as a promising option, given its role as a glutathione precursor with antioxidant, anti-inflammatory, and mitochondrial-protective effects. These mechanisms contribute to reduced cytokine release (IL-6, TNF-α) and hepatocyte apoptosis[12,16]. The dosing schedule in our study was consistent with that recommended for hepatic injury[17]. We found that NAC significantly reduced PES incidence, independent of tumour burden, baseline liver function, or chemotherapeutic dose—findings that align with Siramolpiwat et al[5], who similarly reported a protective effect of NAC versus placebo.Our recent work also demonstrated that combining high-dose DEXA with NAC yielded particularly favorable results, with sharp reductions in PES, mitigation of liver dysfunction, and shorter hospitalisation [4]. However, the independent contributions of each agent in that setting were not clear. Furthermore, as Biolato et al [18] noted, prolonged or high-dose corticosteroid therapy may increase metabolic complications, making NAC an attractive alternative or safer standalone strategy.Although NAC is generally well tolerated, clinicians should remain vigilant for dose-related infusion reactions, especially during the loading phase. Reported adverse effects include flushing, angioedema, bronchospasm, and hypotension [12]. In our trial, side effects were mild and manageable, echoing prior studies [19]. Nevertheless, NAC should be avoided in patients with a history of severe allergy or those with uncontrolled asthma.

Post-procedural liver dysfunction in our study was rare, likely reflecting the predominance of Child–Pugh A patients and the high technical expertise of the operators. To detect more subtle changes, we employed the ALBI score, which offers greater sensitivity than the Child–Pugh system in monitoring hepatic reserve [20]. A key strength of our work is that it represents the first head-to-head comparison of NAC and DEXA for PES prevention, thereby addressing a gap in the existing literature. Beyond measuring PES incidence, we also incorporated dynamic ALBI scoring to provide a more comprehensive assessment of drug safety and hepatic function. By restricting enrollment to BCLC stage B patients, we targeted a high-risk group and reduced confounding by disease stage heterogeneity.

That said, the study has important limitations. The modest sample size reduces statistical power and may affect generalizability, emphasizing the need for larger confirmatory trials. The absence of a placebo control group also limits the interpretation of absolute treatment effects. Future research should investigate additional determinants of PES such as tumour location, embolization selectivity, and procedural variations—that may refine risk stratification. Such work will clarify whether PES prevention strategies should be universally applied or tailored to individual patient subsets.

6. DFT Studies (Chemical Reactivity & Radical Scavenging)

The manuscript presents a comparison between N-Acetylcysteine (NAC) and Dexamethasone (DEX) using key quantum chemical descriptors such as HOMO (Highest Occupied Molecular Orbital), LUMO (Lowest Unoccupied Molecular Orbital), energy gap, ionization potential, electron affinity,

electronegativity, electrochemical potential, hardness, softness, and electrophilicity. These quantum descriptors provide valuable insights into the molecular reactivity of both compounds and their potential therapeutic applications, particularly in the context of Hepatocellular Carcinoma (HCC) and Post-Embolization Syndrome (PES).

The analysis reveals key differences between NAC and DEX in terms of their electronic properties, with important implications for their ability to interact with reactive oxygen species (ROS) and other toxins released during embolization procedures.



Figure. 4 The geometrical optimization of the Dexa and NAC drugs considered in this study.

Observations and Interpretation of Quantum Descriptors:

The HOMO of NAC is -6.36 eV, slightly lower than that of DEX (-6.18 eV), indicating that NAC is more readily able to donate electrons compared to DEX. This feature is significant because a lower HOMO value implies that NAC has a higher tendency to lose electrons, which is a characteristic of "soft" molecules. The LUMO of NAC (-0.40 eV) is higher than that of DEX (-1.45 eV). A higher LUMO indicates that NAC is more easily capable of accepting electrons, which is a characteristic of a "soft" molecule with higher reactivity. The Energy Gap (ΔEGap), which reflects the difference between the HOMO and LUMO energies, is also crucial. NAC has a larger energy gap (5.96 eV) than DEX (4.73 eV), suggesting that NAC is more stable in its ground state but can more readily undergo electronic excitation due to its "soft" nature. A lower energy gap typically facilitates faster chemical reactions when the molecule is exposed to external stimuli, such as ROS [26].

The Ionization Potential (IP) of NAC (6.36 eV) is slightly higher than that of DEX (6.18 eV), while NAC's Electron Affinity (EA) is much lower (0.40 eV) compared to DEX (1.45 eV). These values indicate that NAC is more prone to losing electrons (ionization), and less prone to accepting electrons compared to DEX. This reinforces NAC's "soft" nature, allowing it to engage more readily in redox reactions with ROS, which are released during embolization. The Hardness (η), which measures a molecule's resistance to change in its electron density, is higher for NAC (2.98 eV) than for DEX (2.36 eV). This suggests that NAC has a slightly more rigid electronic structure, which could contribute to its stability. However, Softness (S), which is the inverse of hardness, is lower for NAC (0.34 eV) compared to DEX (0.42 eV). Soft molecules are more reactive and have a greater tendency to interact with other species, such as ROS. The lower softness value for NAC further supports the idea that it is a "soft" molecule

with a high chemical reactivity, making it more efficient at neutralizing ROS and protecting the liver during PES in HCC. NAC exhibits a lower electrophilicity (ω = 1.92 eV) than DEX (3.07 eV), indicating that it is less prone to accepting electrons from nucleophilic agents. While this might suggest that DEX is more electrophilic, NAC's lower electrophilicity is consistent with its ability to act as a "soft" nucleophile, capable of reacting quickly with electrophilic species like ROS during embolization.



Figure 5. Frontier molecular orbitals and their energy gaps for the NAC and DEX Drugs

Table 4. The calculated HOMO-LUMO energy (eV), and the Quantum descriptors for NAC and DEXA Drugs

Property	N-Acetylcysteine (NAC)	Dexamethasone (DEX)
HOMO (eV)	-6.36	-6.18
LUMO (eV)	-0.4	-1.45
Energy Gap (ΔEGap) (eV)	5.96	4.73
Ionization Potential (IP) (eV)	6.36	6.18
Electron Affinity (EA) (eV)	0.4	1.45
Electronegativity (χ) (eV)	3.38	3.81

Electrochemical Potential (μ) (eV)	3.38	3.81
Hardness (η) (eV)	2.98	2.36
Softness (S) (eV)	0.34	0.42
Electrophilicity (ω) (eV)	1.92	3.07

The quantum chemical descriptors reveal that NAC is a "soft" molecule, characterized by a more favorable HOMO-LUMO energy alignment, lower hardness, and greater chemical reactivity compared to Dexamethasone. These properties allow NAC to react rapidly with ROS and other toxic species that are released during embolization, potentially providing a protective effect for the liver in HCC patients. This high chemical reactivity, combined with NAC's ability to donate and accept electrons more readily than Dexamethasone, supports its use as an effective therapeutic agent in managing oxidative stress and liver injury associated with PES [27].

In contrast, Dexamethasone, with its slightly less reactive electronic properties and lower softness, may not engage as quickly or effectively with ROS, making it less suitable for addressing the oxidative stress encountered in HCC patients following embolization. These insights, derived from quantum chemical calculations, should be highlighted in the discussion to strengthen the argument for NAC's superior therapeutic potential in this context.

MESP Analysis for NAC and Dexamethasone:

The manuscript presents a MESP (Molecular Electrostatic Potential) analysis comparing N-Acetylcysteine (NAC) and Dexamethasone. The analysis provides valuable insights into the reactivity and stability of both molecules, crucial for understanding their potential therapeutic actions, particularly in the context of their antioxidant properties in Hepatocellular Carcinoma (HCC).

N-Acetylcysteine (NAC):

The Sulfur (S-H) group in NAC plays a critical role in its chemical reactivity, acting as the "warhead" that neutralizes free radicals. This is well-highlighted in the MESP analysis, where the red region corresponds to the highly electropositive sulfur-hydrogen bond. The presence of this group is a key feature in NAC's ability to act as a nucleophile, readily donating electrons to reactive oxygen species (ROS) or other electrophilic molecules. This "warhead" characteristic explains NAC's effectiveness in combating oxidative stress, particularly in environments where ROS are abundant, such as in post-embolization syndrome (PES) in HCC patients.

The MESP map clearly shows the electron density around the S-H group to be highly reactive, further confirming that NAC can rapidly engage with ROS. This molecular feature underpins NAC's therapeutic efficacy, offering protection against liver damage caused by embolization, as it reacts with and neutralizes free radicals [28].



Figure 6 The DOS of the NAC Drug

Dexamethasone:

In contrast, Dexamethasone appears as a stable, bulky molecule, as suggested by the MESP analysis. The charge distribution across the molecule shows a much more uniform electrostatic potential compared to NAC, with the range from -8.425 e-2 to 8.425 e-2. This indicates a balanced, less reactive distribution of electron density, which is characteristic of a molecule with lower reactivity compared to NAC. Dexamethasone's larger size and rigid structure contribute to its role as a steroid with strong anti-inflammatory properties, but its limited ability to rapidly react with ROS suggests that it might not be as effective in mitigating oxidative damage in the context of PES.

The stable nature of Dexamethasone makes it suitable for modulating inflammation but less ideal for neutralizing free radicals in environments with high oxidative stress. The MESP map suggests that Dexamethasone's electron density is less concentrated at any particular point, unlike NAC's reactive sulfur group.



Figure 7 The DOS of the DEX Drug

The MESP analysis effectively highlights the key differences between NAC and Dexamethasone, supporting the hypothesis that NAC, due to its reactive sulfur group, acts as a "soft" molecule capable of neutralizing ROS and providing antioxidant protection. In contrast, Dexamethasone bulky, stable structure makes it less reactive, limiting its ability to engage with ROS in the same manner. These insights emphasize the importance of NAC's chemical reactivity in the context of treating oxidative stress in HCC, especially following embolization, and suggest why NAC might outperform Dexamethasone in this particular therapeutic setting.



Figure 8 The molecular electrostatic potential maps of the selected compounds

7. Computational Study on Dexamethasone vs. N-Acetylcysteine (NAC) for Post-Embolization Syndrome (PES) in HCC

This is a fascinating study with significant implications for the treatment of Post-Embolization Syndrome (PES) in Hepatocellular Carcinoma (HCC). The study introduces an intriguing paradox: Dexamethasone, a theoretically stronger anti-inflammatory drug, appears to be less effective in treating PES compared to N-Acetylcysteine (NAC). The computational work you present could provide a solid foundation for understanding why NAC outperforms Dexamethasone in this specific clinical setting, but a few critical improvements and clarifications are needed to strengthen the narrative and to align your computational results with your clinical findings.

Scientific Narrative and Hypothesis:

The scientific narrative should emphasize why NAC is more effective in PES treatment than Dexamethasone, despite Dexamethasone being a powerful anti-inflammatory agent. The hypothesis

driving this computational analysis is compelling. Dexamethasone suppresses inflammation, but NAC targets the root cause of PES: Oxidative Stress. Specifically, NAC activates the Nrf2 pathway, the body's master antioxidant switch, by binding to Keap1, thereby addressing the oxidative damage caused by dying liver tumor cells. To fully support your clinical findings and to build a strong scientific case, your computational study should make a clear connection between inflammation, oxidative stress, and liver toxicity, all of which contribute to PES in HCC patients. The drugs in question Dexamethasone and NAC should be assessed based on their ability to interact with the key proteins that regulate these processes.

Inflammation Target (Dexamethasone), Glucocorticoid Receptor (GR), as the main site of action for Dexamethasone, which functions to suppress inflammation. PDB ID: 4P6X (Crystal structure of the Glucocorticoid Receptor). It is reasonable to expect that Dexamethasone binds strongly to the Glucocorticoid Receptor, as this is its primary mode of action. However, inflammation is not the sole cause of PES; the presence of oxidative stress, induced by dying tumor cells, exacerbates the condition. Dexamethasone's effectiveness is limited to the inflammatory aspect and does not address oxidative damage directly. In your computational analysis, you find that Dexamethasone exhibits a very strong docking score of -13.509 with 4P6X. This is consistent with its known action as a potent anti-inflammatory agent. However, this also reinforces the point that Dexamethasone is effective in inflammation management but does not address the broader problem of oxidative stress and ROS accumulation.

Oxidative Stress Target (NAC), Keap1 (Kelch-like ECH-associated protein 1), the primary target for NAC, which helps activate the Nrf2 pathway to combat oxidative stress. PDB ID: 4L7B (Structure of Keap1). NAC binds to Keap1 and activates the Nrf2 pathway, a key regulator of antioxidant responses in the body. This mechanism allows NAC to neutralize ROS and clear toxins released by dying tumor cells, effectively protecting the liver. The docking score for NAC with Keap1 (4L7B) is -3.210, which is less negative than the score for Dexamethasone with the Glucocorticoid Receptor. However, this is expected, as NAC does not function in the same way as Dexamethasone; NAC targets oxidative stress rather than inflammation. The key takeaway here is not just the docking score, but the mechanism of action: NAC's ability to interact with Keap1 and activate the Nrf2 pathway makes it a unique therapeutic option that addresses the root cause of PES oxidative stress rather than just suppressing inflammation.

Liver Toxicity Target, CYP450, specifically CYP3A4, a liver enzyme involved in drug metabolism. PDB ID: 5VCC. In HCC patients, the liver is already weakened, and drug-induced liver toxicity is a major concern. NAC supports the liver's detoxification mechanisms, whereas Dexamethasone may contribute to liver damage due to its long-term effects on metabolism and immune suppression. For NAC, the docking score with CYP3A4 (5VCC) is -8.013, which suggests a reasonable affinity for this enzyme. This is beneficial because it suggests that NAC does not cause significant liver toxicity and might actually help in detoxifying ROS and other harmful molecules during PES treatment.

Conclusion and Recommendations for Computational Study:

This computational study builds an important scientific narrative that highlights NAC's dual ability to treat oxidative stress and protect the liver during PES in HCC patients. By binding to Keap1, NAC activates the Nrf2 pathway, which mitigates oxidative damage and helps the liver recover. On the other hand, Dexamethasone primarily acts as an anti-inflammatory drug by binding to the Glucocorticoid Receptor, but it fails to address oxidative stress and liver toxicity. The docking analysis of NAC with Keap1 (4L7B) and CYP3A4 (5VCC) supports its effectiveness in dealing with oxidative stress and liver

protection. Dexamethasone's docking score with 4P6X shows that it is effective against inflammation but does not address the underlying oxidative damage caused by dying tumor cells. For this study to have a high impact, especially for a journal like Nature, further emphasis on the clinical relevance of NAC's interaction with Keap1 and the Nrf2 pathway should be provided. It would also be beneficial to link these computational results to experimental data or clinical trial outcomes demonstrating NAC's superior efficacy in PES treatment.



Figure 9 illustrates the binding mode of the ligand Dexamethasone within the Glucocorticoid Receptor (GR) complex (PDB ID: 4P6X), presented in both two-dimensional (2D) schematic and three-dimensional (3D) structural representations.



Figure 9 illustrates the binding mode of the ligand N-Acetylcysteine (NAC) within the Glucocorticoid Receptor (GR) complex (PDB ID: 4P6X), presented in both two-dimensional (2D) schematic and three-dimensional (3D) structural representations.



Figure 10 depicts the interaction of the ligand N-Acetylcysteine (NAC) with the KEAP/NRF2 complex (PDB ID: 4L7B), shown in both two-dimensional (2D) and three-dimensional (3D) views



Figure 11 displays the binding interaction of the ligand N-Acetylcysteine (NAC) within the CYP3A complex (PDB ID: 5VCC), presented using both two-dimensional (2D) and three-dimensional (3D) visual models

Table 5. Molecular Docking Results. This table presents the calculated docking scores, specific interaction types, and corresponding binding pocket residues for N-Acetylcysteine (NAC) docked with the target proteins (PDB IDs: 4P6X, 4L7B, and 5VCC) and Dexamethasone (DEXA) docked with the protein from PDB ID 4P6X only.

Ligand	PDB ID	Docking Score	Interactions	Residue
N-Acetylcysteine (NAC)	4P6X	-4.006	1: Salt Bridge, 2: Attractive Charge, 3: Conventional Hydrogen Bond, 4: Pi-Sulfur	PHE623, GLN570, ARG611, LEU563
N-Acetylcysteine (NAC)	4L7B	-3.210	1: Salt Bridge, 2: Water Hydrogen	PRO492, GLU493, ARG494,

			Bond, 3: Carbon Hydrogen Bond, 4: Conventional Bond	HOH832
N-Acetylcysteine (NAC)	5VCC	-8.013	1: Van der waals, 2: Conventional Hydrogen Bond, 3: Alkyl, 4: Conventional Bond	ILE120, PHE304, SER119, MET114, ILE303, ALA305, PHE302, SER299, ALA297, ILE300, GLN298, ILE118, ALA117, GOL602, EDO612, PHE241
Dexamethasone	4P6X	-13.509	Conventional, Carbon Hydrogen Bond, Alkyl, Pi-Alkyl	MET604, CYS736, ASN564, THR739, GLN642, LEU732, MET601, GLN570, ARG611, TRP600

8. Clinical Trial Comparison: N-Acetylcysteine vs. Dexamethasone in Post-Embolization Syndrome in HCC Patients

The comparison between N-Acetylcysteine (NAC) and Dexamethasone for managing Post-Embolization Syndrome (PES) in Hepatocellular Carcinoma (HCC) patients, with a focus on various pharmacokinetic properties predicted through tools like SwissADME. The argument presented is scientifically sound, but there are several aspects that require critical examination. While the study brings new insights, particularly by introducing the paradoxical superiority of NAC over Dexamethasone for this indication, it lacks deeper exploration of the underlying mechanisms that make this comparison relevant to PES, particularly in the context of liver dysfunction.

1. Pharmacokinetic and Pharmacodynamic Considerations:

The pharmacokinetic data for NAC and Dexamethasone presented in the table offer valuable insights into absorption, distribution, metabolism, and excretion (ADME) properties. However, there are key gaps that should be addressed more thoroughly:

- **Absorption and Bioavailability**:

- The comparison between water solubility and Caco2 permeability between NAC and Dexamethasone is useful, but one critical parameter that is not considered here is the effective plasma concentration over time. For HCC patients, particularly those with compromised liver function, the actual bioavailability and pharmacokinetics in the systemic circulation are more important than simple permeability measures. It would be helpful to provide more context around how these absorption parameters translate into therapeutic concentrations at the liver site of action [26, 27].
- Additionally, while both NAC and Dexamethasone show similar intestinal absorption (around 77-78%), it would be prudent to discuss how the liver's reduced capacity to metabolize and clear drugs in HCC might alter these figures.

- **Distribution and Liver-Specific Considerations**:
  - The volume of distribution (VDss) for NAC and Dexamethasone is notably different. NAC shows a significantly more negative VDss value (-1.125) than Dexamethasone (0.176), which may indicate a different tissue distribution profile. However, this point should be contextualized more. Specifically, liver distribution in HCC patients is of utmost importance, and NAC's more negative VDss could suggest poorer liver tissue penetration. It would be beneficial to add information or references regarding NAC's specific liver penetration.
  - The fraction unbound parameter is important, as it can influence drug activity. The higher fraction unbound for NAC (0.709) versus Dexamethasone (0.378) suggests that NAC may have a higher free drug concentration, which could be advantageous in treating oxidative stress. However, the clinical significance of this should be explored in more depth in the discussion [28].
- **CYP Enzyme Interactions**:
  - Both drugs show no significant inhibition or metabolism through key liver enzymes like CYP3A4. While this may be a positive feature in terms of minimizing drug-drug interactions, a more thorough exploration of how liver function in HCC may affect these enzymes would be important. For example, many patients with HCC may have altered CYP enzyme activities due to cirrhosis or other factors, which could impact the predicted pharmacokinetic data.
  - Furthermore, the fact that neither drug is a substrate for CYP2D6 or CYP3A4 might be relevant in minimizing adverse interactions, but this should be linked more explicitly to clinical outcomes in HCC treatment [29].

2. Toxicity and Hepatotoxicity:

The lack of predicted hepatotoxicity for both NAC and Dexamethasone is reassuring, especially given the fragile state of the liver in HCC patients. However, hepatotoxicity is a multifactorial issue in clinical settings, and the data presented does not provide enough context on the mechanisms of liver injury that may still arise with long-term use of these compounds. The lack of hepatotoxicity prediction does not fully account for the complex relationship between a drug's therapeutic window and hepatic injury in patients with existing liver damage. A more detailed analysis of liver toxicity risks in the context of pre-existing liver damage (such as cirrhosis or fibrosis in HCC) is needed.

- The oral rat acute and chronic toxicity (LD50 and LOAEL) data presented for both drugs may not directly correlate with the clinical context of HCC patients. While these preclinical toxicity values provide useful insights, they fail to consider the potential for drug-induced liver injury (DILI) or toxicity in the presence of liver dysfunction. For example, NAC has been shown to

have protective effects in some liver injury models, but this effect is highly context-dependent, particularly in the presence of other comorbidities [30].

3. Scientific Narrative and Clinical Relevance:

The narrative hinges on the idea that while dexamethasone is a stronger anti-inflammatory agent, NAC addresses the root cause of oxidative stress and protects the liver. This is a compelling argument, but the manuscript should provide clearer links between the mechanisms of action and clinical outcomes, particularly in PES.

- The immune suppression of dexamethasone is well-documented, but the oxidative stress pathway targeted by NAC is more complex. NAC acts as an antioxidant, but the underlying molecular mechanisms by which NAC mitigates liver damage in HCC patients should be more explicitly discussed. Does NAC reduce ROS or inflammation? Does it enhance glutathione levels, and how does this relate to liver regeneration or repair in the HCC context?
- A clearer clinical connection should be made between the pharmacokinetic data and patient outcomes. For example, PES in HCC is likely associated with inflammatory and oxidative processes. How do the pharmacokinetics of NAC translate into a clinical reduction of oxidative damage, compared to dexamethasone's immune-modulatory effects? This connection needs to be explored more fully in the results and discussion sections [31].

4. Recommendation for Further Exploration:

- **Longitudinal Data**: A longitudinal clinical trial design is warranted to assess long-term outcomes in terms of liver function (e.g., ALT, AST, bilirubin levels), quality of life, and survival. This would provide stronger evidence for NAC's efficacy in reducing PES and protecting the liver in HCC patients compared to dexamethasone.
- **Oxidative Stress Markers**: The incorporation of biomarkers for **oxidative stress** (e.g., ROS, MDA, glutathione levels) in clinical samples would help bridge the gap between NAC's pharmacodynamics and the observed therapeutic effects. This could solidify the case for NAC's superiority in this context.

Table 6. Pharmacokinetic and toxicity parameters of NAC and DEXA Drugs

Property	Model Name	N-Acetylcysteine Predicted Value	Dexamethasone Predicted Value	Unit
Absorption	Water solubility	-0.064	-4.203	Numeric (log mol/L)
Absorption	Caco2 permeability	0.502	0.832	Numeric (log Papp in 10^{-6} cm/s)

Absorption	Intestinal absorption (human)	78.549	77.777	Numeric (% Absorbed)
Absorption	Skin Permeability	-2.735	-3.886	Numeric (log Kp)
Absorption	P-glycoprotein substrate	No	Yes	Categorical (Yes/No)
Absorption	P-glycoprotein I inhibitor	No	No	Categorical (Yes/No)
Absorption	P-glycoprotein II inhibitor	No	No	Categorical (Yes/No)
Distribution	VDss (human)	-1.125	0.176	Numeric (log L/kg)
Distribution	Fraction unbound (human)	0.709	0.378	Numeric (Fu)
Distribution	BBB permeability	-0.372	-0.889	Numeric (log BB)
Distribution	CNS permeability	-3.475	-3.387	Numeric (log PS)
Metabolism	CYP2D6 substrate	Yes	No	Categorical (Yes/No)
Metabolism	CYP3A4 substrate	No	No	Categorical (Yes/No)
Metabolism	CYP1A2 inhibitior	No	No	Categorical (Yes/No)
Metabolism	CYP2C19 inhibitior	No	No	Categorical (Yes/No)
Metabolism	CYP2C9 inhibitior	No	No	Categorical (Yes/No)
Metabolism	CYP2D6 inhibitior	No	No	Categorical (Yes/No)

Metabolism	CYP3A4 inhibitior	No	No	Categorical (Yes/No)
Excretion	Total Clearance	0.309	0.674	Numeric (log ml/min/kg)
Excretion	Renal OCT2 substrate	No	No	Categorical (Yes/No)
Toxicity	AMES toxicity	No	No	Categorical (Yes/No)
Toxicity	Max. tolerated dose (human)	1.563	-0.103	Numeric (log mg/kg/day)
Toxicity	hERG I inhibitor	No	No	Categorical (Yes/No)
Toxicity	hERG II inhibitor	No	No	Categorical (Yes/No)
Toxicity	Oral Rat Acute Toxicity (LD50)	1.578	2.406	Numeric (mol/kg)
Toxicity	Oral Rat Chronic Toxicity (LOAEL)	1.456	2.634	Numeric (log mg/kg_bw/day)
Toxicity	Hepatotoxicity	No	No	Categorical (Yes/No)
Toxicity	Skin Sensitisation	No	No	Categorical (Yes/No)
Toxicity	*T.Pyriformis* toxicity	0.284	0.298	Numeric (log ug/L)
Toxicity	Minnow toxicity	3.104	1.927	Numeric (log mM)

9. Conclusion

In this study, N-acetylcysteine (NAC) demonstrated a significantly lower risk of post-embolization syndrome (PES) compared to Dexamethasone (DEXA), with its benefits remaining consistent regardless of short-term liver function recovery. These findings suggest that NAC is the more effective prophylactic strategy for PES in patients with BCLC stage B HCC and well-preserved hepatic reserve. The data underscore NAC's potential in mitigating oxidative stress and providing liver protection, factors that DEXA does not address. While NAC's superior efficacy in PES prevention is evident, future studies with larger cohorts and targeted intermediate-stage subgroups are necessary to further elucidate its role, particularly in the context of liver ischemia–reperfusion injury. The computational data supports these clinical observations, but further refinement and deeper integration of pharmacokinetic and mechanistic insights are needed to fully bridge the gap between computational predictions and clinical outcomes. With these adjustments, this study has the potential to significantly enhance our understanding of PES management in HCC patients and establish NAC as a more reliable option for managing oxidative stress in liver protection.

References

[1] C. N. Sternberg *et al.*, "Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial," 2023.

[2] D. J. van der Windt *et al.*, "Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis," *Hepatology*, vol. 68, no. 4, pp. 1347–1360, Oct. 2018, doi: 10.1002/HEP.29914.

[3] X. Zhao, Y. Xia, S. Jin, and Y. Wang, "Squamous Cell Carcinoma Overlying Cervical Myoma," *J. Minim. Invasive Gynecol.*, vol. 29, no. 1, pp. 14–15, Jan. 2022, doi: 10.1016/j.jmig.2021.09.711.

[4] S. Selvaraj *et al.*, "Role of degrading hydrogels in hepatocellular carcinoma drug delivery applications: A review," *J. Drug Deliv. Sci. Technol.*, vol. 95, p. 105628, 2024, doi: https://doi.org/10.1016/j.jddst.2024.105628.

[5] D. Rayapati, K. A. McGlynn, J. D. Groopman, and A. K. Kim, "Environmental exposures and the risk of hepatocellular carcinoma," *Hepatol. Commun.*, vol. 9, no. 2, p. e0627, 2025.

[6] N. Di Tommaso, A. Gasbarrini, and F. R. Ponziani, "Intestinal barrier in human health and disease," *Int. J. Environ. Res. Public Health*, vol. 18, no. 23, 2021, doi: 10.3390/ijerph182312836.

[7] M. Camilleri, K. Madsen, R. Spiller, B. G. Van Meerveld, and G. N. Verne, "Intestinal barrier function in health and gastrointestinal disease," *Neurogastroenterol. Motil.*, vol. 24, no. 6, pp. 503–512, 2012, doi: 10.1111/j.1365-2982.2012.01921.x.

[8] C. Strell, K. Lang, B. Niggemann, K. S. Zaenker, and F. Entschladen, "Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1," *Exp. Cell Res.*, vol. 316, no. 1, pp. 138–148, Jan. 2010, doi: 10.1016/j.yexcr.2009.09.003.

[9] Z. H. Bao, X. Bin Hou, H. L. Li, Y. F. Mao, and W. R. Wang, "The mechanism and progress of ferroptosis in pancreatic cancer," *Acta Histochem.*, vol. 124, no. 6, p. 151919, 2022, doi: 10.1016/j.acthis.2022.151919.

[10] G. Chen, G. Guo, X. Zhou, and H. Chen, "Potential mechanism of ferroptosis in pancreatic cancer (Review)," *Oncol. Lett.*, vol. 19, no. 1, pp. 579–587, 2020, doi: 10.3892/ol.2019.11159.

[11] S. Thomas, F. Glahn, and H. Foth, "Effects of heavy metals and tobacco smoke condensate on the glutathione-level in cultured human lung cells," *Toxicol. Lett.*, vol. 189, pp. S224–S225, Sep. 2009, doi: 10.1016/j.toxlet.2009.06.526.

[12] D. Grimm *et al.*, "Growing tissues in real and simulated microgravity: New methods for tissue engineering," *Tissue Eng. - Part B Rev.*, vol. 20, no. 6, pp. 555–566, 2014, doi: 10.1089/ten.teb.2013.0704.

[13] L. T. Rabi *et al.*, "Potential new cancer biomarkers revealed by quantum chemistry associated with bioinformatics in the study of selectin polymorphisms," *Heliyon*, vol. 10, no. 7, Apr. 2024, doi: 10.1016/j.heliyon.2024.e28830.

[14] M. S. Ummah, "No 主観的健康感を中心とした在宅高齢者における健康関連指標に関する共分散構造分析Title," *Sustain.*, vol. 11, no. 1, pp. 1–14, 2019, [Online]. Available: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI

[15] D. E. Longnecker, F. J. Manning, and M. H. Worth, *R E V I E W O F N A S A ' S Longitudinal Study AstronautHealth*.

[16] X. Wang, X. Zhu, M. Kashif Anwar, Q. Meng, and N. Zhong, "Evaluating the Role of AI and Empirical Models for Predicting Regional Economic Growth and Transportation Dynamics: An Application of Advanced AI Approaches," *Int. J. Transp. Sci. Technol.*, no. xxxx, 2024, doi: 10.1016/j.ijtst.2024.08.007.

[17] R. Bai, A. Rebelo, J. Kleeff, and Y. Sunami, "Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis," *Lipids Health Dis.*, vol. 20, no. 1, pp. 1–12, 2021, doi: 10.1186/s12944-021-01476-y.

[18] Y. Cui *et al.*, "The lipid droplet in cancer: From being a tumor-supporting hallmark to clinical therapy," *Acta Physiol.*, vol. 240, no. 3, pp. 1–15, 2024, doi: 10.1111/apha.14087.

[19] M. S. Petrov, "Fateful fat: Intra-pancreatic lipids cause pancreatic cancer," *Cell Reports Med.*, vol. 5, no. 2, p. 101428, 2024, doi: 10.1016/j.xcrm.2024.101428.

[20] H. Chen, R. Ma, B. Zhou, X. Yang, F. Duan, and G. Wang, "Integrated immunological analysis of single-cell and bulky tissue transcriptomes reveals the role of interactions between M0 macrophages and naïve CD4+ T cells in the immunosuppressive microenvironment of cervical cancer," *Comput. Biol. Med.*, vol. 163, no. May, p. 107151, 2023, doi: 10.1016/j.compbiomed.2023.107151.

[21] R. Adolph, *済無No Title No Title No Title*. 2016.

[22] S. L. Wuest, S. Richard, S. Kopp, D. Grimm, and M. Egli, "Simulated microgravity: Critical review on the use of random positioning machines for mammalian cell culture," *Biomed Res. Int.*, vol. 2015, 2015, doi: 10.1155/2015/971474.

[23] Y. Sunami, A. Rebelo, and J. Kleeff, "Lipid droplet-associated factors, PNPLA3, TM6SF2, and HSD17B proteins in hepatopancreatobiliary cancer," *Cancers (Basel).*, vol. 13, no. 17, 2021, doi: 10.3390/cancers13174391.

[24] D. Tang, X. Chen, R. Kang, and G. Kroemer, "Ferroptosis: molecular mechanisms and health implications," *Cell Res.*, vol. 31, no. 2, pp. 107–125, 2021, doi: 10.1038/s41422-020-00441-1.

[25] M. Vancamelbeke and S. Vermeire, "The intestinal barrier: a fundamental role in health and disease," *Expert Rev. Gastroenterol. Hepatol.*, vol. 11, no. 9, pp. 821–834, 2017, doi: 10.1080/17474124.2017.1343143.

[26] Abbas, M. A., Mahar, J., Hameed, N., & Rasool, M. S. (2025). DFT-Guided Design of a Low-Band-Gap Pyrazoline Scaffold: The Critical Role of a Para-Nitro Substituent. *Multidisciplinary Surgical Research Annals*, *3*(3), 461-503.

[27] Atif, H. M., Shahzad, A., Khan, M. Z., Abbas, M. A., & Mahar, J. (2025). Design of Novel drug as Potential Anti-Prostate Cancer Activity: Thiophene Derivatives against prostate cancer cell line as therapeutic agents using Pharmacokinetics molecular docking and DFT studies. *Indus Journal of Bioscience Research*, *3*(6), 548-559.

[28] Abbas, M. A., Mahar, J., Rasool, M. S., Khan, M. J., & Khan, M. Z. (2025). The Dual Therapeutic Promise of Quinoa: Exploring Antidiabetic and Antioxidant Effects through Experimental and Computational Models. *Multidisciplinary Surgical Research Annals*, *3*(3), 504-544.

[29] Abbas, M. A., Mahar, J., Khan, M. J., Rasool, M. S., & Khan, M. Z. (2025). IN SILICO INVESTIGATION OF 3, 6-DIPHENYL-[1, 2, 4] TRIAZOLO [3, 4-B][1, 3, 4] THIADIAZOLE DERIVATIVES AS EGFR MODULATORS FOR LUNG CANCER TREATMENT. *The Cancer Research Review*, *4*(2), 243-308.

[30] Abbas, M. A., Khan, M. Z., Atif, H. M., Shahzad, A., & Mahar, J. (2025). Computer-Aided Analysis of Oxino-bis-Pyrazolederivative as a Potential Breast Cancer Drug Based on DFT, Molecular Docking, and Pharmacokinetic Studies: Compared with the Standard Drug Tamoxifen. *Indus Journal of Bioscience Research*, *3*(6), 535-537.

[31] Abbas, M. A. (2025). Advanced Synthesis and Multifunctional Characterization of Neodymium-Doped $Ba_2NiCoFe_{28-x}O_{46}$ X-Type Hexagonal Ferrites: A Comprehensive Study of Structural, Morphological, and Electromagnetic Properties. *Sch Acad J Biosci*, *8*, 1213-1227. Abbas, M. A. (2025). Advanced Synthesis and Multifunctional Characterization of Neodymium-Doped $Ba_2NiCoFe_{28-x}O_{46}$ X-Type Hexagonal Ferrites: A Comprehensive Study of Structural, Morphological, and Electromagnetic Properties. *Sch Acad J Biosci*, *8*, 1213-1227.